ISLT revoked:

https://www.sec.gov/litigation/admin/2017/34-81395.pdf

ISLT SEC Suspension for delinquent Financials/Filings:

https://www.sec.gov/litigation/suspensions/2017/34-81240.pdf

Order:

https://www.sec.gov/litigation/suspensions/2017/34-81240-o.pdf

Admin Proceeding:

https://www.sec.gov/litigation/admin/2017/34-81239.pdf

8k out

'On March 17, 2017, XR 22 Inc. acquired shares of the Company’s preferred stock from ISLT in accordance with agreements between XR 22 Inc. and ISLT' https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11952191

New BOD

President Gary F. Blackburn bio http://www.bloomberg.com/research/stocks/private/person.asp?personId=26612130&privcapId=223174526

Also holding some patents http://patents.justia.com/inventor/gary-f-blackburn?page=2

Matthew Carangelo is working for AstraZeneca
https://www.linkedin.com/in/matthew-carangelo-4b9a967/

CEO Thomas Leonard. Not sure, might be this guy https://www.linkedin.com/in/tom-leonard-2007265/

Lets go baby!

Anybody have any idea why the positive movement in price over the past couple of days?

12's falling

This is the beginning of a much bigger move imo

SO SHARES ARE NO LONGER RESTRICTED??? BUMMER...

§ISLT Out @ HA HA...get this... .0911!!§
-62% OUCH! That one hurt.

News = Death...RIP Islet
§ISLT

A little volume on the heels of a CT Order. Get that financing? Now, if we could just get a ruling.
Sorry, talking to myself, again...
§ISLT

Which is:

" NAFLD and NASH are both closely associated with diabetes and obesity, and together are now considered a leading cause of liver disease. Consequently there is an urgent need for effective treatment options for these diseases. NASH is due, in part, to insulin resistance and oxidative stress resulting from steatosis, or accumulation of fat in the liver. A phase 2b clinical study of once-daily remogliflozin etabonate for NASH is anticipated to initiate in 2015.

In clinical studies, remogliflozin etabonate was shown to significantly improve insulin sensitivity and beta cell function, as well as reduce body weight and levels of alanine aminotransferase (ALT). In pre-clinical studies, remogliflozin etabonate significantly reduces fat accumulation in the liver and causes a marked reduction in the levels of circulating markers of oxidative stress. Unlike other drugs of its class (SGLT2 inhibitors), remogliflozin etabonate has intrinsic anti-oxidant activity, which may reverse the steatohepatitis and oxidative stress associated with the maintenance and progression of NASH.

The clinical study consisted of 336 treatment-naive subjects with type 2 diabetes and an HbA1c between 7.0% and 9.5%. Subjects were equally randomised to each of the remogliflozin etabonate treatments (50, 100, 250, 500 or 1000 mg twice daily), matching placebo or 30 mg pioglitazone (once daily). At Week 12, remogliflozin etabonate improved insulin sensitivity by 6-33% and beta cell function by 23-43%. Patients receiving remogliflozin etabonate also had significant weight loss (1.4-3.6 kg vs placebo). Importantly, post-hoc analysis of changes in ALT indicated that remogliflozin etabonate-treated subjects with elevated baseline ALT showed statistically significant (p < 0.049) mean reductions of 32-42% at Week 12 as compared to placebo.

"In multiple trials to date, remogliflozin etabonate has been shown to be a safe and potent anti-diabetic compound. In addition to its ability to reverse insulin resistance and cause weight loss, it also uniquely offers intrinsic anti-oxidant activity, which may prove useful in the treatment of patients with NAFLD and NASH," said William Wilkison, Ph.D., COO, Islet Sciences, Inc. "
http://globenewswire.com/news-release/2015/04/23/727749/10130447/en/Islet-Sciences-Inc-Presented-at-50th-International-Liver-Conference.html


§ISLT

ISLT COO William Wilkison presented some interesting data on the potential for remogliflozin etabonate in NAFLD today at the ICL in Vienna.

§ ISLT - Take that, you scurvy knave! §
Ha Ha Ha! Gonna get a ruling...
§ISLT

Are we ever gonna get any indication?

Hey NITE! It's days like today I have a good mind to HIT YOU for that entire 175K. Might want to lower that front a little...
§ISLT

§ ISLT NEWS: 8K Update - BHV LA §
Let's see that Reg Statement!
§ISLT

knowshewantsomeshares....
§ISLT

seriously....a man that writes in CAPS must KNOW!!

ANOTHER SCAM!!!!!!!!!!!!!!!!!

§ ISLT Figuring her out! §
Large blocks available down-low on the AON
Snatched another 40K @ .23! She's paper thin on top....gotta fish.
§ISLT

Added today. This is going to pop.
§ISLT

§ ISLT In @ .2 §
§ISLT

I have some news for you folks that do not believe in the coming success of this stock. Diabetes is not going away, however it would be nice if an easier treatment program was possible, and I do believe that this is the company to so it. So do yourself a large favor and buy as much of this stock as your budget will support.

ISLT is smells like a winner

I slit the sheet, The sheet I slit and on the slitted sheet I ISLT.

ISLT is having perfect play

Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green







Print


Alert



Islet Sciences, Inc. (QB) (USOTC:ISLT)
Intraday Stock Chart

Today : Thursday 12 December 2013
Click Here for more Islet Sciences, Inc. (QB) Charts. Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green

RALEIGH, NC--(Marketwired - Dec 12, 2013) - Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)

Dear Islet Shareholder,

It is with great pleasure that I begin to communicate with our shareholders about the future of Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) (the "Company" or "Islet"). Dr. Wilkison, Islet's COO, and I have been working together for several years at both GlaxoSmithKline and BHV Pharma, and are now excited to have joined the team at Islet. While our vision is long term, expectations for near-term success are high. In recent months, our Company has faced significant challenges. But the commitment from your Board to see Islet through these difficult times has been unwavering. The Board's efforts on this front are a clear testament to the Company's pipeline and its potential to positively impact the lives of patients suffering from diabetes.

We are committed to building our brand of translating great science into value by changing the way clinicians and their patients think about the diagnosis and treatment of metabolic disease. Metabolic diseases, diabetes in particular, are unfortunately a growth market with vast unmet needs. On the one hand we still do not fully understand the mechanism behind the onset of type 1 diabetes where the result of an autoimmune dysfunction leads to a lifetime of exogenous insulin dependence. On the other, social and demographic trends associated with every-day life continue to contribute to the rapid worldwide growth in incidence rates of type 2 diabetes. The work that we do is important because the growing population of diabetic patients is in need of new, more effective, and better tolerated treatments.

Our mission is to pursue near-term value generating catalysts while challenging ourselves to think long-term and develop a sustainable business model. Our daily efforts will focus on patients and their doctors, to better understand their needs and deliver to them actionable commercial solutions in a way that is efficient for shareholders.

So you can expect to begin seeing some changes fairly shortly. Not necessarily in our scientific focus, but in the way we approach the business of being the best company we can be. We hope to create shareholder value every day and ultimately position Islet as a recognized leader in the development of therapeutics and diagnostics for the treatment and care of patients with metabolic disease. Some recent changes we have made that are directed at increasing shareholder value are as follows:
•In November we conducted the Company's first ever formal portfolio review of all development programs. During this process, we enlisted the help of an external panel of highly skilled experts in various scientific and pharmaceutical fields. This review provided clarity and vision for how best to move each program forward while stimulating creative ideas for additional opportunities to explore.
•We are consolidating operations centrally under a one-company/one-pipeline strategy as we move away from independently managed programs.
•The Company has begun to address deficiencies in its internal control structure by instituting more rigorous controls and hiring another member of the finance team in support of our Chief Financial Officer.
•Important steps have been taken to solidify all of the Company's relationships with key partner organizations. This work is ongoing but we believe these relationships are strong and mutually committed.
•We have also initiated business development initiatives aimed at partnering for the strategic development of existing programs as well as in-licensing additional programs. The Company has ongoing negotiations with multiple parties and we are excited about what we see on the horizon and what these efforts may eventually mean for Islet.
•Lastly, we have begun the process of transitioning the company's headquarters to Research Triangle Park, NC ("RTP"), one of the country's top life sciences industry clusters. RTP has an active ecosystem of pharmaceutical and biotech companies, including the country's greatest concentration of clinical research organizations, and is surrounded by three prominent research universities.

This transition period will continue to be challenging in the near term. But with the commitment from your Board and management, and the support of our partners, I am confident that the Islet of the not so distant future will look and feel dramatically different from where we are today. I am excited to be a part of Islet Sciences and am confident this transition will lead to a bright future for our Company.

James Green

CEO, Islet Sciences, Inc.

About Islet Sciences
Islet Sciences is a biopharmaceutical company developing novel technologies for the diagnosis and treatment of patients suffering from metabolic diseases. For more information: www.isletsciences.com

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements for Islet Sciences, Inc. reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science, Inc.'s reports filed with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of the Company's control.


Contact:
Investor Relations
Islet Sciences, Inc.
8601 Six Forks Rd, Suite 400
Raleigh, NC 27615
919.480.1518
info@isletsciences.com

ISLT neato looking chart pinging bottom buster scans today.. ne1 here adding more shares?

http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=islt&insttype=&freq=1&show=&time=6

Oh, My! ISLT did 45 for 1 R/S, POS! Should NOT have bought!

Zut! Dumping back to $0.16! No good at all.

Very strong close with 11500 shares buy at $0.30. Going back to dollars soon, as little shares to sell now.

Still low. Was $4 Apr 1. Back to $2-$3.

$ISLT @ .35!

$ISLT @ .30!

ISLT, because it was as High as $6! $0.25 is just a peanut.

what's up?

13:08 2/23/2012 ONCE One E-Commerce Corp Common Stock ONCED Islet Sciences, Inc. NEW Common Stock 1-45 R/S **


http://otcbb.com/asp/dailylist_detail.asp?d=02/22/2012&mkt_ctg=ALL

ONCE @ .10!

On January 10, 2012, Islet Sciences, Inc. (“Islet”), a wholly-owned subsidiary of One E-Commerce Corporation (the “Registrant”), entered into an agreement (the “Agreement”) with Progenitor Cell Therapy (“PCT”), a wholly owned subsidiary of NeoStem Inc. Under the Agreement, PCT will be providing the protocols, procedures, systems, equipment, testing, quality controls, and manufacturing and distribution services to support the development and commercialization of Islet’s encapsulated porcine islet cells for the treatment of diabetes.


As compensation for the services of PCT, Islet agreed to pay to PCT a non-refundable monthly fee of $63,000 and a non-refundable monthly charge of between $33,000 and $54,000. PCT is also entitled to receive 400,000 shares of the Registrant’s common stock and warrants to purchase 350,000 shares of the Registrant’s common stock at an exercise price of $1.00 per share.


PCT has the right for a period of ten years to be the exclusive manufacturer of any product involved in the services to be provided under the Agreement. With respect to commercial production of such products, PCT will be entitled to a royalty of 2.85% of gross sales and 5% of any sublicensing fees, royalties, milestone fees or profit sharing payments.


The foregoing description of the Agreement is qualified in its entirety by the text of the Agreement which is annexed hereto as Exhibit 10.1.


On January 12, 2012, Islet issued a press release announcing execution of the Agreement, a copy of which is attached hereto as Exhibit 99.1.

ONCE Monster in the making, just follow the news...

ONCE News!
http://www.otcmarkets.com/stock/ONCE/news
QualityStocks News - One E-Commerce Corp. Subsidiary Signs Alliance and Service Agreement with Progenitor Cell Therapy

Scottsdale, AZ, Jan 13, 2012 (PRWeb.com via COMTEX) -- QualityStocks would like to highlight One E-Commerce Corp., a publicy traded company. The company's wholly-owned subsidiary, Islet Sciences, is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes. Islet's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells.
In the company's news yesterday,

One E-Commerce Corp. wholly-owned subsidiary, Islet Sciences, Inc., a development-stage biotech firm with key intellectual property in transplantation therapy for insulin-dependent diabetics, reported signing an important services agreement with wholly-owned subsidiary of leading custom-tailored cell therapy developer/manufacturer NeoStem Inc., Progenitor Cell Therapy.

Progenitor provides complete cGMP-compliant manufacturing capabilities and consulting services which allow for supreme mastery over development and commercialization aspects related to pioneering new therapies. Progenitor delivers full-spectrum support covering all aspects of the process from early infancy in product development, through to end-phase operations like manufacturing, storage and transportation of cell products.

This key agreement will see Progenitor handling the appropriate logistical requirements (protocols, procedures, equipment, manufacturing, quality control and distribution, etc.) for the development/commercialization of Islet's revolutionary Type I diabetes treatment, an encapsulated porcine islet cell-based approach that shows real potential.

The market potential of a Type I diabetes treatment is obvious and the company is moving quickly to file with the FDA, preparing an IND for this year. This agreement then is a huge step towards crystallizing the technology and creating the commercial springboard required to launch the eventual product into the stratosphere. Indeed, Phase I clinical trials are currently in planning and Islet is very excited to move forward with what is arguably some of the most interesting technology to emerge in the diabetes space.

CEO of Islet Sciences, John Steel, boldly spoke of his confidence in the science and technology underlying this treatment, which has been refined at Islet over the last 13 years. Steel called Progenitor the perfect partner for advancing this important technology towards commercialization and reminded investors of the potential an effective treatment for Type I diabetes would have. Steel also hailed the reputation Progenitor has earned for their expertise and ability to consistently deliver full support for nurturing precisely such innovative cell therapy services to fruition.

Chairman and CEO of NeoStem, Robin L. Smith, MD, MBA, pledged to bring the full range of support services available to bear on the task at hand and called the move a "great opportunity for Progenitor Cell Therapy", not only to meet the vast and growing unmet needs of the some 25.8M people in the US alone who suffer from diabetes (ADA), but to prove just how capable the organization truly is.

Islet filed an 8-K with the SEC on Jan 6, announcing closing of the deal.

About QualityStocks

ONCE .243 up, no shares available!

$$$$$ ONCE 8k $$$$$$$

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8336102


New York, NY (January 12, 2012) –Islet Sciences, Inc., a wholly-owned subsidiary of One E-Commerce Corporation (OTC.BB : ONCE) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that the company has signed a services agreement with Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem Inc. (NYSE AMEX: NBS), and a leader in providing custom-tailored cell therapy services.

Under this agreement, PCT will be providing the protocols, procedures, systems, equipment, testing, quality controls, and manufacturing and distribution services to support the development and commercialization of ISI’s encapsulated porcine islet cells for the treatment of diabetes.

The company plans to file an IND with the FDA in 2012, and the agreement is a key element in preparing for, and the commencement of the subsequent planned Phase I clinical trials.

“Progenitor Cell Therapy is the perfect partner for Islet Sciences as it embarks on developing a practical and effective treatment for Type I diabetes,” said John Steel, CEO of Islet Sciences. “With over thirteen years invested in research and development, we are confident in our science and our approach, and prepared to move to the next level. Progenitor’s expertise and well-earned reputation for quality in supporting cell therapy services will be critical to our success.”

“The American Diabetes Association estimates that in the US alone, over 8%, or 25.8 million people have diabetes, with 1.9 million new cases reported in 2010, “said Robin L. Smith, MD, MBA, Chairman and Chief Executive Officer of NeoStem, Inc. “Providing our full range of services toward the development and commercialization of such a novel treatment to meet this large and growing unmet medical need, is certainly an exciting project and a great opportunity for Progenitor Cell Therapy.”

On January 6, 2012, Islet Sciences filed a Current Report on Form 8-K with the Securities and Exchange Commission announcing the closing of the merger of Islet Sciences, Inc. with a subsidiary of One E-Commerce Corporation, a Nevada Corporation.

About Progenitor Cell Therapy
Progenitor Cell Therapy (PCT) provides client-based cell therapy services that support the development and commercialization of cellular therapies. PCT provides cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality system strategies. Services include a full spectrum of support and consulting related to process and product development, validation, due diligence evaluations, tissue collection, processing, and storage, product manufacturing, distribution and transportation


About NeoStem, Inc.
NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, Inc., also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and has commenced enrollment in a Phase 2 trial for the preservation of heart function after a heart attack. Amorcyte expects to begin a Phase 1 clinical trial in 2012 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with its partner Becton-Dickinson. NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as we know it today.

For more information on NeoStem, please visit www.neostem.com .




--------------------------------------------------------------------------------



About Islet Sciences, Inc.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes. The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company’s mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.

ONCE Filing Alert:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8333687

ONCE more news today!:
ALLENDALE, N.J., Jan. 12, 2012 /PRNewswire via COMTEX/ -- NeoStem's cell therapy manufacturing division, Progenitor Cell Therapy ("PCT"), a NeoStem, Inc. company (NYSE Amex: NBS) ("NeoStem" or the "Company"), announced today an agreement whereby PCT will provide contract manufacturing and regulatory services related to the development of Islet Sciences - PTM, which will be an injectable suspension of microencapsulated insulin-producing, pancreatic islet cells which are harvested from designated pathogen free pigs. As part of this arrangement, PCT will perform microencapsulation for parsing beta pancreatic islets for xenotransplantation using piglet pancreata. Islet Sciences, Inc. ("Islet") is a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes and is a wholly-owned subsidiary of One E-Commerce Corporation (OTCBB: ONCE).
A 2010 study by the CDC found that approximately 25.8 million Americans, more than 8% of the population, were affected by diabetes. 5% of this number, approximately 1.3 million, have type 1 diabetes. Type 1 diabetes is estimated to cost the US $14.4 billion total annually.

"Given the robust market opportunity and the potential for cell therapy to alter the disease paradigm, NeoStem has agreed to this novel arrangement whereby PCT will subsidize manufacturing margin related to current services for Islet Sciences - PTM product in exchange for royalties on future sales, exclusive manufacturing rights for both clinical trial and commercial manufacturing and an equity stake in Islet's parent. We recognize that PCT's track record of developing cell therapies cost efficiently for cell therapy companies makes this a truly compelling opportunity in the industry," said John Steel, CEO of Islet Sciences.

"Our team looks forward to applying its process and assay expertise, in partnership with the scientific expertise of Dr. Jonathan Lakey, scientific advisor to Islet, and his team, towards the development of this novel and creative cellular therapeutic for the treatment of type 1 diabetes," said Robert A. Preti, PhD, President of PCT. "We are honored that Islet Sciences has enlisted PCT to provide manufacturing and development support as it advances this important product through clinical development."

Dr. Robin L. Smith, Chairman and CEO of NeoStem, added, "We are excited to begin using our manufacturing currency at PCT to support important technologies with promise by providing manufacturing and regulatory support at a reduced profit margin in exchange for participation in future royalties, equity as well as a commitment for clinical trial and commercial manufacturing exclusivity."

About Type 1 Diabetes

According to the American Diabetes Association, type 1 diabetes, previously called insulin-dependent diabetes mellitus (IDDM) or juvenile diabetes, is an autoimmune disease characterized by insulin deficiency resulting from destruction of beta-cells in the pancreas, ultimately resulting in the body's inability to convert consumed sugar and starches into energy. This form of diabetes usually affects children and young adults, but it can occur at any age. Although insulin therapy and other treatments can be used to manage the condition, the condition is currently incurable.

About NeoStem, Inc.

ONCE Breaking news!

NEW YORK, Jan 12, 2012 (GlobeNewswire via COMTEX) -- Islet Sciences, Inc., a wholly-owned subsidiary of One E-Commerce Corporation (OTCBB:ONCE) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that the company has signed a services agreement with Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem Inc. (NYSE Amex:NBS), and a leader in providing custom-tailored cell therapy services.
Under this agreement, PCT will be providing the protocols, procedures, systems, equipment, testing, quality controls, and manufacturing and distribution services to support the development and commercialization of ISI's encapsulated porcine islet cells for the treatment of diabetes.

The company plans to file an IND with the FDA in 2012, and the agreement is a key element in preparing for, and the commencement of the subsequent planned Phase I clinical trials.

"Progenitor Cell Therapy is the perfect partner for Islet Sciences as it embarks on developing a practical and effective treatment for Type I diabetes," said John Steel, CEO of Islet Sciences. "With over thirteen years invested in research and development, we are confident in our science and our approach, and prepared to move to the next level. Progenitor's expertise and well-earned reputation for quality in supporting cell therapy services will be critical to our success."

"The American Diabetes Association estimates that in the US alone, over 8%, or 25.8 million people have diabetes, with 1.9 million new cases reported in 2010," said Robin L. Smith, MD, MBA, Chairman and Chief Executive Officer of NeoStem, Inc. "Providing our full range of services toward the development and commercialization of such a novel treatment to meet this large and growing unmet medical need, is certainly an exciting project and a great opportunity for Progenitor Cell Therapy."

On January 6, 2012, Islet Sciences filed a Current Report on Form 8-K with the Securities and Exchange Commission announcing the closing of the merger of Islet Sciences, Inc. with a subsidiary of One E-Commerce Corporation, a Nevada Corporation.

About Progenitor Cell Therapy

Progenitor Cell Therapy (PCT) provides client-based cell therapy services that support the development and commercialization of cellular therapies. PCT provides cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality system strategies. Services include a full spectrum of support and consulting related to process and product development, validation, due diligence evaluations, tissue collection, processing, and storage, product manufacturing, distribution and transportation.

About NeoStem, Inc.

Hmmm, nice news out.. will this stock ever get decent volume?

ONCE 8k Jan. 06, 2012
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8328471

ONCE Chart:
http://www.profitspi.com/stock-chart.aspx?id=ONCE&ca=427429852

ONCE level 2:
.08, .229, .243, .25(2)!